Greenwich LifeSciences’ (GLSI) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Greenwich LifeSciences (NASDAQ:GLSI) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $38.00 target price on the stock.

Greenwich LifeSciences Stock Performance

Shares of GLSI opened at $12.01 on Tuesday. Greenwich LifeSciences has a 52 week low of $8.15 and a 52 week high of $21.44. The stock has a market capitalization of $157.93 million, a price-to-earnings ratio of -15.01 and a beta of 1.69. The stock has a fifty day moving average of $12.73 and a 200-day moving average of $13.57.

Insider Activity

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 3,200 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00. Following the acquisition, the chief executive officer now owns 5,539,302 shares in the company, valued at approximately $61,597,038.24. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders bought 10,500 shares of company stock worth $128,459. Insiders own 51.67% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

Several large investors have recently made changes to their positions in GLSI. Garden State Investment Advisory Services LLC bought a new position in Greenwich LifeSciences in the 3rd quarter valued at about $253,000. Barclays PLC lifted its position in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after buying an additional 3,005 shares in the last quarter. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.